The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
The Memory Clinic of Department of Neurology, Chengdu Western Hospital, Chengdu, China.
J Alzheimers Dis. 2021;83(4):1521-1536. doi: 10.3233/JAD-201560.
Given that there is no specific drug to treat Alzheimer's disease, non-pharmacologic interventions in people with subjective cognitive decline (SCD) and amnestic mild cognitive impairment (aMCI) are one of the most important treatment strategies.
To clarify the efficacy of blue-green (500 nm) light therapy on sleep, mood, and physiological parameters in patients with SCD and aMCI is an interesting avenue to explore.
This is a monocentric, randomized, and controlled trial that will last for 4 weeks. We will recruit 150 individuals aged 45 years or older from memory clinics and divide them into 5 groups: SCD treatment (n = 30), SCD control (n = 30), aMCI treatment (n = 30), aMCI control (n = 30), and a group of healthy adult subjects (n = 30) as a normal control (NC).
The primary outcome is the change in subjective and objective cognitive performance between baseline and postintervention visits (4 weeks after baseline). Secondary outcomes include changes in performance assessing from baseline, postintervention to follow-up (3 months after the intervention), as well as sleep, mood, and physiological parameters (including blood, urine, electrophysiology, and neuroimaging biomarkers).
This study aims to provide evidence of the impact of light therapy on subjective and objective cognitive performance in middle-aged and older adults with SCD or aMCI. In addition, we will identify possible neurophysiological mechanisms of action underlying light therapy. Overall, this trial will contribute to the establishment of light therapy in the prevention of Alzheimer's disease.
鉴于目前尚无治疗阿尔茨海默病的特效药物，对有主观认知下降（SCD）和遗忘型轻度认知障碍（aMCI）的人群进行非药物干预是最重要的治疗策略之一。
探讨蓝绿（500nm）光疗法对 SCD 和 aMCI 患者睡眠、情绪和生理参数的疗效，这是一个很有趣的研究方向。
这是一项单中心、随机、对照试验，将持续 4 周。我们将从记忆诊所招募 150 名年龄在 45 岁或以上的个体，并将他们分为 5 组：SCD 治疗组（n=30）、SCD 对照组（n=30）、aMCI 治疗组（n=30）、aMCI 对照组（n=30）和一组健康成年对照组（n=30）。
主要结局是在基线和干预后访视（基线后 4 周）之间主观和客观认知表现的变化。次要结局包括从基线、干预后到随访（干预后 3 个月）的表现变化，以及睡眠、情绪和生理参数（包括血液、尿液、电生理学和神经影像学生物标志物）的变化。
本研究旨在为蓝绿（500nm）光疗法对 SCD 或 aMCI 中老年人主观和客观认知表现的影响提供证据。此外，我们将确定光疗法作用的可能神经生理机制。总的来说，这项试验将有助于确立光疗法在预防阿尔茨海默病中的地位。
